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ORIGINAL ARTICLEEpidemiologic characteristics associated with ST23 clones compared
to ST1 and ST47 clones of Legionnaires disease cases in FranceP. Cassier1,2,3,4,5,6, C. Campese7, Y. Le Strat7, D. Che7, C. Ginevra1,2,3,4,5,6, J. Etienne1 and S. Jarraud1,2,3,4,5,6
1) Hospices Civils de Lyon, National Reference Centre of Legionella, Centre de Biologie Est, 2) CIRI, International Center for Infectiology Research, Legionella
Pathogenosis Team, Université de Lyon, 3) Inserm, U1111, 4) Ecole Normale Supérieure de Lyon, 5) Université Lyon 1, Centre International de Recherche en
Infectiologie, 6) CNRS, UMR5308, Lyon and 7) French Institute for Public Health Surveillance, Saint Maurice, FranceAbstractIn France, approximately 1200 cases of Legionnaires disease (LD) are reported annually, and isolates are available for approximately 20% of
cases identiﬁed since 2000. All Legionella pneumophila serogroup 1 (sg1) isolates are characterized by sequence-based typing at the National
Reference Centre. LD cases caused by L. pneumophila sg1 reported from 2008 through 2012 were considered for the study. Our study
objective was to describe cases according to their sequence type (ST). We also constructed multivariable modiﬁed Poisson regression
models to estimate the incidence rate ratio (IRR) and to identify characteristics potentially associated with ST23 clones compared to ST1
and ST47 clones. We studied 1192 patients infected by ST1 (n = 109), ST23 (n = 236), ST47 (n = 123) or other STs (n = 724). The
geographic distribution of the ST23 cases across the country was signiﬁcantly different compared to other ST groups. This genotype was
signiﬁcantly associated with the absence of corticosteroid therapy compared to ST1 (IRR = 0.56; p 0.016). Concerning exposure, the
ST23 genotype was signiﬁcantly less associated with hospital-acquired infections compared to ST1 (IRR = 0.32; p 0.001), but it was more
associated with infections acquired in hospitals and elderly settings compared with ST47. Finally, the ST23 genotype was less frequently
associated with travel than other STs. Despite the large number of cases of ST23 infection, we did not identify any characteristics speciﬁc
to this ST. However, we identiﬁed independent associations between ST1 and nosocomial transmission and steroid therapy. These
ﬁndings should encourage further exploration, especially in terms of environmental diffusion, strain virulence and host factors.
New Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: pierre.cassier@chu-lyon.frIntroductionLegionnaires disease (LD) is usually acquired through inhalation
of aerosolized water contaminated with Legionella spp., which is
found ubiquitously in natural and man-made aqueous environ-
ments such as cooling towers, hot water systems or whirlpoolsNew Microbes and New Infections © 2014 The Authors. Published by Els
This is an open access arti[1]. Legionella pneumophila, especially serogroup 1 (sg1), is the
major cause of LD, which remains a serious disease. Several
host-related risk factors have been clearly identiﬁed [2–4],
including older age, male sex, smoking, diabetes, chronic heart
or lung disease, cancer or hematologic malignancy and steroid
use or any immunosuppressive therapy.
The characterization of clinical isolates by molecular typing
methods is essential for epidemiologic investigations, particu-
larly for clusters and outbreaks. Thus, L. pneumophila sg1 iso-
lates can be characterized by sequence-based typing (SBT) using
isolates or by nested-PCR-based SBT using clinical samples
[5,6]. The typing method for L. pneumophila sg1 was developed
by the European Working Group for Legionella Infections
(EWGLI was renamed the European Study Group for LegionellaNew Microbe and New Infect 2015; 3: 29–33
evier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
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FIG. 1. Division of metropolitan France into ﬁve regions to determine
geographic distribution of cases.
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wide sequence types (STs), such as ST1, ST23, ST37, ST47 and
ST62, have been identiﬁed [7–12]. In France, ST1- and ST47-
associated LD represented 9% and 11% of culture-proven
cases in 2008, respectively [7]. The epidemiologic characteris-
tics of these two STs have previously been published: ST1
strains with the Paris pulsotype were more frequently identiﬁed
among elderly patients, immunocompromised patients or
women and had a high lethality rate (38%) compared to spo-
radic strains. In contrast, ST47 strains were signiﬁcantly more
frequently associated with smoking, but the case fatality rate
was lower than with sporadic strains [13].
The present French epidemiologic report shows that the ST
most frequently associated with LD is ST23. It accounted for
approximately 20% of the strains isolated in France in 2008, but
no speciﬁc host factors associated with this genotype have been
reported thus far [7]. We thus characterized the epidemiologic
and clinical features of 236 patients infected with ST23 and
compared them to those of patients infected by two other
predominant STs (ST1, ST47) and other nonpredominant STs.Materials and MethodsSource of information
In France, all cases of LD are reported to the national health
authority (Institut de Veille Sanitaire), which collects epidemio-
logic information through anonymous mandatory notiﬁcation,
including various risk factors and exposure routes for LD. The
notiﬁcation form allows the collection of information on current
illness, the patient’s personal characteristics (sex, age and post-
code of residence), disease outcome and factors known to be
associated with LD. Moreover, exposure to any of the following
settings during the 10-day period preceding symptom onset (i.e.
the incubation period) is also recorded: hospital, elderly setting,
thermal centre, whirlpool spa or travel site (campsite, hotel) [7].
Additionally, all corresponding Legionella isolates are sent to
the NRCL (national reference centre for Legionella), where they
are characterized by SBT [6].
Included cases
In our study, cases presenting clinical and radiologic signs of
pneumonia combined with L. pneumophila sg1 isolation from a
culture of sputum or bronchopulmonary secretions (bron-
choalveolar lavage ﬂuid or bronchial aspirate) were included.
Cases of LD due to L. pneumophila sg1 reported from 2008
through 2012 were considered for the study. All patients lived in
metropolitan France. The geographic distribution of cases (based
on the postcode of residence) was used as a proxy for the
geographic distribution of strains, and the patients were thenNew Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceclassiﬁed into ﬁve regions according to their telephone area code
(Fig. 1). Finally, on the basis of genotype distribution, for the
purposes of the study, the population was divided into four
groups: ST1, ST23, ST47 and other ST culture-conﬁrmed cases.
Statistical analysis
We constructed multivariable modiﬁed Poisson regression
models to estimate the incidence rate ratio (IRR) and to identify
characteristics potentially associated with ST23 compared to
the three other groups, considering a p value of 0.05 to be
signiﬁcant [14]. Analyses were performed by Stata 11.2 (Sta-
taCorp, College Station, TX, USA) software.ResultsFrom 2008 to 2012, a total of 6458 cases of LD were reported,
and Legionella isolates were recovered in 1192 cases (18.5%),
which were included in the study. ST23 accounted for the
largest number of isolates (n = 236), representing 19.8% of all
clinical strains. This rate did not change signiﬁcantly from year
to year over the study period. ST1 and ST47 L. pneumophila
represented 9.1% and 10.3% of all isolates, respectively. ST23
isolates were found ubiquitously across France, but mainly in
regions 3 and 4 (76.4%); this strain was also found in LD cases
from other ST groups with only minor differences. On the
other hand, ST1 cases occurred mostly in regions 1 and 4, and
ST47 cases were mainly found in region 3 (Fig. 1; Table 1).
Patients infected with L. pneumophila sg1 ST23 had a mean
age of 59.1 years and were mostly men (Table 1). Of these
patients, 72.9% had at least one of the risk factors associated
with LD in 72.9%. This percentage was not signiﬁcantly different
from the corresponding percentages among patients infected byEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 3, 29–33.
nses/by-nc-nd/3.0/)
TABLE 1. Epidemiologic characteristics of ST23 cases compared to ST1, ST47 other STs and all cases of Legionnaires disease due
to Legionella pneumophila serogroup 1 in France, 2008–2012
Characteristic ST23 ST1 ST47 Other ST All
No. of subjects 236 109 123 724 1192
Male 190 (80.5%) 80 (73.4%) 101 (82.1%) 576 (79.6%) 947 (79.5%)
Age (years) (mean/variable) 59.1 63.3 60.6 58.7 59.4
Death 35 (16.1%) 30 (30.9%) 15 (13.2%) 124 (18.6%) 204 (18.6%)
Risk factor
At least one 172 (72.9%) 82 (75.2%) 85 (69.1%) 540 (79.6%) 879 (73.7%)
Cancer 19 (8.1%) 26 (23.9%) 13 (10.6%) 80 (11.1%) 138 (11.6%)
Steroid therapy 10 (4.2%) 24 (22.0%) 12 (9.8%) 68 (9.4%) 114 (9.6%)
Diabetes 42 (17.8%) 13 (11.9%) 24 (19.5%) 107 (14.8%) 186 (15.6%)
Tobacco 124 (52.5%) 31 (28.4%) 55 (44.7%) 370 (51.1%) 580 (48.7%)
Exposure
Hospital-acquired infection 7 (3.0%) 34 (31.2%) 3 (2.4%) 45 (6.2%) 89 (7.5%)
Travel 29 (12.3%) 12 (11.0%) 21 (17.1%) 142 (19.6%) 204 (17.1%)
Elderly setting 9 (3.8%) 6 (5.5%) 0 14 (1.9%) 29 (2.4%)
Region
1 27 (11.4%) 44 (40.4%) 16 (13.0%) 94 (13.0%) 181 (15.2%)
2 13 (5.5%) 13 (11.9%) 17 (13.8%) 114 (15.8%) 157 (13.2%)
3 88 (37.3%) 14 (12.8%) 73 (59.4%) 229 (31.6%) 404 (33.9%)
4 93 (39.4%) 37 (33.9%) 13 (10.6%) 219 (30.3%) 362 (30.4%)
5 15 (6.4%) 1 (0.9%) 4 (3.3%) 68 (9.4%) 88 (7.4%)
ST, sequence type.
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factors associated with ST23 LD were steroid therapy (4.2%) or
cancer (8.1%). Conversely, smoking was the most frequently
reported risk factor (n = 124; 52.5%). The percentage of cases
with this risk factor was highest in the ST23 group compared to
the other three groups. Moreover, ST23 cases were rarely
hospital acquired (3.0%) or acquired in elderly settings (3.8%).
Travel-associated cases represented 12.3% of the ST23 cases.
Multivariate analysis comparing the characteristics of ST 23
cases with those of other groups revealed ﬁve signiﬁcant dif-
ferences (Table 2). First, the geographic distribution of ST23
cases was signiﬁcantly different than the geographic distribution
of other STs (Table 2). Second, this genotype was signiﬁcantly
less associated with steroid therapy compared to ST1 (IRR =
0.56; p 0.016). This difference was not observed whenTABLE 2. Multivariate analysis of epidemiologic characteristics of S
Characteristic
ST23 vs. ST1 (n [ 345)
p
ST23 vs.
IRR (95% CI) IRR (95%
Male 1.08 (0.92–1.26) 0.35 1.02 (0.86
Age (years) (mean/variable) 1.00 (0.99–1.0) 0.81 1.00 (0.99
Risk factor
Cancer 0.75 (0.55–1.03) 0.07 0.93 (0.70
Steroid therapy 0.56 (0.35–0.90) 0.016* 0.68 (0.43
Diabetes 1.05 (0.91–1.21) 0.55 0.99 (0.82
Tobacco 1.04 (0.92–1.17) 0.58 1.11 (0.95
Exposure
Hospital-acquired infection 0.32 (0.16–0.63) 0.001* 1.49 (1.03
Travel 0.97 (0.79–1.17) 0.73 0.89 (0.70
Elderly setting 0.95 (0.64–1.40) 0.78 1.69 (1.31
Region <10−3a
1 Ref. Ref.
2 1.14 (0.71–1.81) 0.60 0.68 (0.43
3 1.85 (1.38–2.47) <10−3* 0.88 (0.67
4 1.61 (1.20–2.16) 0.001* 1.43 (1.12
5 1.95 (1.47–2.60) <10−3 1.30 (0.94
ST, sequence type; IRR, incidence rate ratio; CI, conﬁdence interval; Ref., reference.
*Statistically signiﬁcant.
aGlobal test.
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This is an open access articomparing ST23 to ST47 or ST23 to other STs. Concerning
exposure route, the ST23 genotype was signiﬁcantly less
associated with hospital-acquired infections compared to ST1
(IRR = 0.32; p 0.001), but it was more associated with hospital-
acquired infections as well as with infections acquired in elderly
settings compared to ST47. Finally, the ST23 genotype was less
frequently associated with travel cases than other STs.DiscussionIn this study, we found a high rate of ST23 detection in LD; this
ST represents 19.8% of cases with positive cultures in France
between 2008 and 2012. This proportion is higher than those
found in other countries, e.g. 6% in Belgium (2000–2010) [8],T23 cases compared to ST1, ST47 and other STs
ST47 (n [ 359)
p
ST23 vs. other STs (n [ 960)
pCI) IRR (95% CI)
–1.20) 0.81 1.06 (0.80–1.40) 0.67
–1.00) 0.46 1.00 (0.99–1.00) 0.85
–1.24) 0.62 0.81 (0.53–1.24) 0.33
–1.09) 0.11 0.56 (0.31–1.02) 0.06
–1.18) 0.87 1.09 (0.82–1.45) 0.58
–1.31) 0.19 0.99 (0.77–1.26) 0.91
–2.14) 0.034* 0.69 (0.34–1.41) 0.31
–1.13) 0.34 0.66 (0.47–0.95) 0.023*
–2.20) <10−3 1.54 (0.88–2.70) 0.13
<10−3a,* 0.003a
Ref.
–1.08) 0.10 0.44 (0.24–0.80) 0.007*
–1.14) 0.33 1.12 (0.77–1.64) 0.56
–1.83) 0.004* 1.17 (0.80–1.70) 0.42
–1.76) 0.11 0.73 (0.41–1.28) 0.27
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[15] and 0 observed in England and Wales (2000–2008) [11]. A
compilation of European data (3200 isolates from 36 countries)
showed that ST23 accounted for only 10.7% of clinical isolates,
including French strains [16]. The results and statistical com-
parisons in the present work pertain to patients with culture-
proven LD. The inclusion of only these patients could be a
critical source of bias. Throughout the study period, consid-
ering all cases of non-culture-proven LD with complete allelic
proﬁles determined by nested-PCR-based SBT (n = 70), the
ST23 genotype was detected in 28.6% of patients (data not
shown). This proportion is consistent with the number of ST23
culture-proven LD cases of our study.
It also appeared that 72.9% of the ST23-infected patients had
at least one of the risk factors usually associated with LD
acquisition. This overall percentage did not differ from those
observed for cases of LD due to other ST; however, a more
detailed analysis of the different risk factors showed that pa-
tients infected by ST23 strains were less likely to have received
corticosteroid therapy than patients with ST1 (IRR = 0.56;
p 0.016). Corticosteroids or other immunosuppressive thera-
pies (e.g. anti-TNF-α) are increasingly used to treat systemic
diseases such as rheumatoid arthritis, Crohn disease or cuta-
neous psoriasis. The use of these types of medications was
shown to be associated with an increased relative risk of LD,
leading to a 1.6- to 8-fold increase in the risk of LD compared
to the general population [17]. The overall standardized inci-
dence ratio was 13.1 for patients receiving TNF-α antagonists in
the French population [18]. The frequency with which ST23-
infected patients are receiving corticoids suggests that they
are less likely to have chronic diseases requiring hospital
admission. This ﬁnding is consistent with our observations,
which revealed that ST23 infections were more often com-
munity acquired compared to ST1 infections. Indeed, the
observed IRR was low (IRR = 0.32; p 0.001).
Comparing ST23 vs. ST1 cases regarding hospital exposure
and corticosteroid therapy conﬁrmed speciﬁc features related
to ST1 strains that have already been reported [13]. In this
study, 22% of ST1 patients received corticosteroids, and a high
proportion of these patients were hospitalized (31.2%). Of
course, we veriﬁed that there was no regional effect associated
with these nosocomial infections (data not shown). The com-
bination of environmental factors, strain virulence and host
susceptibility may explain the observed differences among STs.
Thus, concerning ST1 strains, we could hypothesize that they
are either very well adapted to hospital water networks or are
widely present in the environment. European data showed that
ST1 accounted for 21.4% of environmental isolates, which is a
relatively high percentage compared to other STs [16]. Other
studies have also shown that ST1 was the most dominant ST inNew Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceanalysed strains from the environment in China (81/164, 49.4%)
and in the United States (73/149, 49%) [19,20]. Moreover, in
the Chinese study, ST1 accounted for 92.3% and 53.1% of the
environmental sg1 isolates from potable water systems and
cooling towers, respectively. This ﬁnding emphasises that ST1
strains are widely present in artiﬁcial water sources, but to our
knowledge, these strains were never reported speciﬁcally in
hospital water networks. Therefore, designing a ST1-speciﬁc
PCR for rapid detection and identiﬁcation in hospital environ-
mental samples would be helpful. We could then hypothesize
that this clone would be more ubiquitous and have lower
virulence, infecting mainly immunocompromised patients.
Finally, another approach would be for L. pneumophila ST1 to
contain speciﬁc virulence determinants adapted for immuno-
compromised patients, who may also present speciﬁc host
characteristics. The epidemiologic characteristics of ST1 cases
could explain the higher case fatality rate observed with this
clone (Table 1).
By contrast, both the ST47 and ST23 strains were rarely
recovered from environmental samples [11,21]. European data
indicated that ST47 and ST23 accounted for 0.4% and 1.5% of
environmental isolates, respectively [16]. These rates suggest
that these strains could have a peculiar virulence pattern because
they are less disseminated in the environment and are less
associated with patients receiving corticosteroids. Nevertheless,
the ST23 genotypewasmore frequently associatedwith hospital-
acquired infections and with infections acquired in elderly set-
tings compared to ST47. We might therefore hypothesize that
the source of infection could be different for these two clones.
Finally, although ST23 isolates could have developed a
peculiar virulence pattern adapted to a larger population, we
should have observed at least as many travel-associated cases in
the ST23 group as we did in the other ST groups. In our study,
this genotype was less frequently associated with travel cases
than other STs. We unfortunately have no explanation for this
difference. All of these observations suggest that ST23 could be
a dominant infective clone in the global population of Legionella
strains, as could ST1 and ST47. Nevertheless, there are still
several unresolved issues, and further analysis will be necessary
to determine the key host characteristics and virulence factors
associated with susceptibility to these clones. Finally, this study
reminds us that it is important to maintain clinician awareness
of the need to collect sputum samples in order to document LD
cases and to better understand the association between host
characteristics and Legionella strains.Conﬂict of InterestNone declared.European Society of Clinical Microbiology and Infectious Diseases, NMNI, 3, 29–33.
nses/by-nc-nd/3.0/)
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